10X Genomics Hits New 52-Week High of $29.92, Showcasing Strong Growth

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 29.92 on June 1, 2026. This achievement marks a notable increase from its 52-week low of USD 8.95, reflecting a robust performance over the past year. In the last 12 months, 10X Genomics has demonstrated a strong performance with a gain of 33.41%, outperforming the S&P 500, which recorded a 28.56% increase during the same period. The company's market capitalization stands at USD 2,132 million, indicating its position as a small-cap entity within the industry. Despite being loss-making, the company maintains a price-to-book ratio of 2.68, which provides insight into its valuation relative to its assets. Additionally, the debt-to-equity ratio of -0.64 suggests a unique financial structure, while the return on equity stands at -10.80%. As 10X Genomics continues to navigate the competitive landscape of biotechnology, its recent price achievement underscores its evolving market presence.